Loading
companiesCompany
Maia Biotechnology
Maia Biotechnology is a United States-based biotechnology company running 2 late-stage cancer trials in non-small-cell lung cancer.
Overview
Maia Biotechnology, based in Chicago, the United States, is a biotechnology company. Maia Biotechnology is a clinical-stage biopharmaceutical company that develops telomere-targeting immunotherapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in non-small-cell lung cancer. The largest, NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Chicago, US
Scorecard
All companies#130of 1244 companies, score 44
- approved products +6
- targets +2
- modalities +2
- regions +6
- 24-month regulatory events +2
- registry trials +26
1 approved, 0 in phase 3, 0 earlier, 1 targets, 174 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
ApprovedMonoclonal antibody (anti-PD-1)
Cemiplimab · Libtayo
A PD-1 blocker that is the standard for advanced skin squamous cell carcinoma, and in 2025 became the first adjuvant immunotherapy for it.
Similar pages
- TrialA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small
Shares Cemiplimab, Non-small-cell lung cancer.
- TrialPhase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Shares Cemiplimab, Non-small-cell lung cancer.
- TrialBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Shares Cemiplimab, Non-small-cell lung cancer.
- TrialA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small
Shares Cemiplimab, Non-small-cell lung cancer.
- TrialA Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce
Shares Cemiplimab, Non-small-cell lung cancer.
- TrialA Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult
Shares Cemiplimab, Non-small-cell lung cancer.
- TrialA Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Shares Cemiplimab, Non-small-cell lung cancer.
- TrialAdding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth
Shares Cemiplimab, Non-small-cell lung cancer.